Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer

Tsujitani, Shunichi; Fukuda, Kenji; Kaibara, Nobuaki

doi:10.1007/s10120-003-0223-x

Cited by 19 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy after hepatectomy was administered in 6 patients using S-1 [7][8][9], cisplatin, 5-FU, and UFT at the discretion of each attending surgeons. After the hepatectomy, all the patients were followed up in the outpatient clinic every 3-4 months, annual measurements of the serum CEA and CA19-9 and annual CT scan were performed.…”

Section: Resultsmentioning

confidence: 99%

“…Surgical resection of liver metastasis from gastric cancer (LMGC) is rarely indicated, because LMGC is often associated with extrahepatic disease, such as peritoneal dissemination, lymph node metastasis, and direct cancer invasion of other organs [1]. Most of the patients with LMGC are thus treated by systemic administration or hepatic arterial infusion of 5-FU, adriamycin, mitomycin C (MMC), cisplatin, and/or S-1 [3][4][5][6][7][8][9] (Table I). The response rates and median overall survival time of patients treated with chemotherapeutic regimens have been reported to be 25-73% and 7-15 months, respectively, and the longterm survival is dismal.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer

Sakamoto¹,

Sano

Shimada³

et al. 2007

Journal of Surgical Oncology

152

145

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer

Sakamoto¹,

Sano

Shimada³

et al. 2007

Journal of Surgical Oncology

152

145

View full text Add to dashboard Cite

show abstract

“…Regarding S-1 plus low-dose cisplatin for gastric cancer, numerous case reports [13,14,15,16], several retrospective or feasibility studies [17,18,19,20] and several phase I studies [6,7,8,9] have been reported in this decade, suggesting promising clinical efficacies. The regimens in these reports included weekly, twice a week, 3 times a week and 5 times a week of cisplatin administrations with various doses, ranging from 3 to 20 mg/m 2 .…”

Section: Discussionmentioning

confidence: 99%

Phase II Trial of S-1 plus Low-Dose Cisplatin for Unresectable and Recurrent Gastric Cancer (JFMC27-9902 Step2)

Nakata

Tsuji²,

Mitachi³

et al. 2010

Oncology

View full text Add to dashboard Cite

Aims: The efficacy and the toxicity of oral fluorouracil derivative S-1 plus low-dose cisplatin in unresectable or recurrent gastric cancer were evaluated by a phase II study. Methods: S-1 was administered orally for 28 days following 14 days’ rest at 80–120 mg/body/day, depending on body surface area. During administration of S-1, cisplatin was given twice a week at the recommended dose (10 mg/m²), which was determined by a phase I study. Data from 34 patients in phase II and 8 patients treated with the recommended dose of cisplatin in phase I were analyzed. The primary endpoint was objective response. Results: The response rate was 47.1%. The median survival time was 11.0 months and the median progression-free survival was 6.9 months. The grade 3/4 toxicities observed in 10% or more of the treated patients were neutropenia (16.7%), anemia (16.7%) and anorexia (11.9%). The serum concentration of cisplatin was 794 ± 341 ng/ml at day 25 of the first course. Conclusions: S-1 plus low-dose cisplatin may be a clinically useful regimen for unresectable or recurrent gastric cancer because of its infrequent adverse events in spite of considerable efficacy and its convenience of no hydration and no hospitalization.

show abstract

“…It was reported that middle-dose-weekly and low-dose-daily regimens also produced high response rates in phase I and II studies [17][18][19]. Furthermore, several trials have been conducted using taxanes (docetaxel and paclitaxel) or irinotecan in combination with S-1.…”

Section: Discussionmentioning

confidence: 99%

Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer

et al. 2005

View full text Add to dashboard Cite

chemotherapy regimens using biochemical modulation and/or combination therapies have improved the prognosis of patients with gastric cancer. S-1 is an oral anticancer agent that was developed based on the theory of the biochemical modulation of 5-FU. S-1 is composed of tegafur (FT, a prodrug of 5-FU), 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate (Oxo), at a molar ratio of 1 : 0.4 : 1 [1]. CDHP inhibits the biodegradation of 5-FU, and Oxo reduces 5-FUinduced gastrointestinal toxicities. In summary, S-1 not only increases the anticancer activity but also reduces the adverse reactions of 5-FU. In clinical studies, as a single agent, S-1 has demonstrated a higher response rate against gastric cancer compared to any other anticancer agent [2][3][4]. S-1 has become one of the drugs used in first-line chemotherapy for advanced or recurrent gastric cancer in Japan.In an attempt to increase the efficacy of S-1, several combination chemotherapy regimens using S-1 have been examined, and cisplatin (CDDP) has received attention as a result of its remarkable activity. Koizumi et al.[5] performed a phase I/II study of S-1 plus CDDP for patients with advanced gastric cancer. S-1 was administered at a standard dose for 3 weeks, and the recommended dose of CDDP, infused on day 8, was 60 mg/ m 2 ; this study revealed an overall response rate of 74%. Baba et al. [6] treated 12 patients using the same schedule, and showed a response rate of 66.7%. These results suggested the excellent therapeutic efficacy of the combination of S-1 and CDDP in the treatment of gastric cancer. However, the effect of the combination therapy on survival has been unclear.The aim of the present study was to evaluate the long-term outcome of combination therapy of CDDP and S-1. We compared, retrospectively, the clinical results of treatment with S-1 alone and treatment with S-1 plus CDDP in patients with advanced or recurrent gastric cancer who were treated in our hospital. AbstractBackground. Although combination therapy of S-1 and cisplatin (CDDP) has excellent efficacy against gastric cancer, the effect of the treatment on survival has been unclear. The aim of this study was to evaluate the long-term outcome of this combination therapy. Methods. Sixty-three patients with advanced or recurrent gastric cancer were treated with S-1, with or without CDDP, as first-line chemotherapy, and the clinical results were compared retrospectively. S-1 was administered orally at a standard dose of 80 mg/m 2 . In the treatment of the S-1 group, S-1 was given for 28 consecutive days, followed by a 14-day rest. In the treatment of the S-1/CDDP group, S-1 was given for 21 consecutive days, followed by a 14-day rest, and CDDP, at 60 mg/m 2 , was infused on day 8. Results. The incidence of adverse reactions of more than grade 3 was 22.5% in the S-1 group and 43.5% in the S-1/ CDDP group, and the treatment compliance was better in the S-1 group. The overall response rate was 25.9% in the S-1 group, and 36.8% in the S-1/CDDP group. The combination of S-1 with...

show abstract

Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer

Cited by 19 publications

References 24 publications

Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer

Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer

Phase II Trial of S-1 plus Low-Dose Cisplatin for Unresectable and Recurrent Gastric Cancer (JFMC27-9902 Step2)

Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer

Contact Info

Product

Resources

About